

Publiseringsrapport og Metodenotat

Organon (Norge) AS – Verdioverføringer til helsepersonell og helseorganisasjoner 2025													Date of publication: 15-June-2026	
	Full Name	HCPs: City of Principal Practice HCOs: city where registered	Country of Principal Practice	Principal Practice Address	Unique country identifier <i>OPTIONAL</i>		Contribution to costs of Events (<i>Art. 3.01.1.b & 3.01.2.a</i>)			Fee for service and consultancy (<i>Art. 3.01.1.c & 3.01.2.c</i>)			TOTAL <i>OPTIONAL</i>	
	(<i>Art. 1.01</i>)	(<i>Art. 3</i>)	(<i>Schedule 1</i>)	(<i>Art. 3</i>)	(<i>Art. 3</i>)	Donations and Grants to HCOs (<i>Art. 3.01.1.a</i>)	Sponsorship agreements with HCOs / third parties appointed by HCOs to manage an Event	Registration Fees	Travel & Accommodation	Fees	Related expenses agreed in the fee for service or consultancy contract, including travel & accommodation relevant to the contract			
HCPs	INDIVIDUAL NAMED DISCLOSURE - one line per HCP (i.e. all transfers of value during a year for an individual HCP will be summed up: itemization should be available for the individual Recipient or public authorities' consultation only, as appropriate)													
	BJØRK, Marte-Helene	BERGEN	NO	Haukelandsveien 22		N/A	N/A			28 400,00			28 400,00	
	HODNELAND, Endre	OS	NO	Hamneveien 48		N/A	N/A			10 000,00			10 000,00	
	TRONVIK, Erling Andreas	TRONDHEIM	NO	Edvard Griegs gate 8		N/A	N/A			30 000,00	3 498,98		33 498,98	
	VESTERBEKKMO, Elisabeth Kleivhaug	TRONDHEIM	NO	Prinsesse Kristinas gate 3		N/A	N/A			15 000,00			15 000,00	
	OTHER, NOT INCLUDED ABOVE - where information cannot be disclosed on an individual basis for legal reasons													
	Aggregate amount attributable to transfers of value to such Recipients - <i>Art. 3.02</i>					N/A	N/A							
	Number of Recipients in aggregate disclosure - <i>Art. 3.02</i>					N/A	N/A							
% of the number of Recipients included in the aggregate disclosure in the total number of Recipients disclosed - <i>Art. 3.02</i>					N/A	N/A						N/A		
HCOs	INDIVIDUAL NAMED DISCLOSURE - one line per HCO (i.e. all transfers of value during a year for an individual HCO will be summed up: itemization should be available for the individual Recipient or public authorities' consultation only, as appropriate)													
	Cardiocon AS	OSLO	NO	Seterveien 3 E						15 000,00			15 000,00	
	Dagens Medisin	Oslo	NO	Tullins gate 6			75 000,00						75 000,00	
	Lipidklubben	Oslo	NO	Sognsvannsveien 9			10 000,00						10 000,00	
	Nansen Neuroscience Network	Oslo	NO	Gaustadalléen 21			95 608,00						95 608,00	
	Norsk cardiologisk selskap- Hjerterforum	OSLO	NO	Christiania Torv 5			120 900,00						120 900,00	
	Norsk sykepleierforbund- Helsesykepleierne NSF	OSLO	NO	Tollbugata 22			63 643,00						63 643,00	
	Norsk sykepleierforbund-NSF - faggruppe for kardiologi	Oslo	NO	Tollbugata 22			18 000,00						18 000,00	
	Norsk sykepleierforbund-NSF - faggruppe for nevrosykepleiere	Oslo	NO	Tollbugata 22			15 650,00						15 650,00	
	Norwegian Society for Cerebrovascular Research	OSLO	NO	Frederik Stangs gate 14C			9 580,00						9 580,00	
	Sykehuset Østfold Kalnes- Nevrologisk avd	Grålum	NO	Kalnesveien 300			30 000,00						30 000,00	
	Vestnorsk Cardiologisk Forening	BERGEN	NO	Jonas Lies vei 65			32 500,00						32 500,00	
	OTHER, NOT INCLUDED ABOVE - where information cannot be disclosed on an individual basis for legal reasons													
	Aggregate amount attributable to transfers of value to such Recipients - <i>Art. 3.02</i>													
	Number of Recipients in aggregate disclosure - <i>Art. 3.02</i>													
% of the number of Recipients included in the aggregate disclosure in the total number of Recipients disclosed - <i>Art. 3.02</i>												N/A		
R & D	AGGREGATE DISCLOSURE													
	Transfers of Value re Research & Development as defined - <i>Article 3.04 and Schedule 1</i>												N/A	

Organon Norway: Methodological Note for HCP/HCO Disclosure 2025

Contents

Organon Norway – Methodological Note	2
Introduction	2
1. Definitions	2
1.1 Recipients.....	2
1.2 Kind of ToVs	2
2. Disclosure’s Scope	3
2.1 Products concerned.....	3
2.2 Company concerned	3
2.4 ToVs date	3
2.5 Direct ToVs.....	4
2.6 Indirect ToVs	4
2.7 Non-monetary ToVs	4
2.8 ToVs in case of partial attendances or cancellation and refund	4
2.9 Cross-border activities.....	4
2.10 R&D.....	4
2.11 Voluntary disclosure.....	4
3. Specific considerations	4
3.1 Country unique identifier	4
3.2 Self-incorporated HCP.....	4
3.3 Multi-year agreements.....	5
4. Data protection legal basis.....	5
4.1 Consent collection.....	5
4.2 Legitimate interests.....	5
5. Form of disclosure	5
5.1 Date of publication.....	5
5.2 Disclosure platform.....	5
5.3 Disclosure language.....	5
6. Disclosure financial data.....	5
6.1 Currency	5
6.2 VAT included or excluded.....	6
6.3 Calculation rules.....	6
7. Additional Information.....	6

Organon Norway: Methodological Note for HCP/HCO Disclosure 2025

Version: Last updated 9 June 2026

Country: Norway

Data year: 2025

Year of publication: 2026

Organon Norway – Methodological Note

Introduction

This Methodology Statement defines the relevant types of transfers to be disclosed, which transfers are excluded, and other relevant information to assist the reader understand how Organon collected, organized and reported the disclosed data in Norway. It follows the mandatory EFPIA standardised structure to support clarity and comparability of disclosure information.

1. Definitions

1.1 Recipients

Healthcare Professional (HCP): Any natural person that is a member of the medical, dental, pharmacy or nursing professions, or any other person who, as part of their professional activities, may prescribe, purchase, supply or administer a medicinal product, and whose primary practice or principal professional address is in Norway. This includes any official or employee of a governmental agency or other organisation that may prescribe, purchase, supply or administer medicinal products.

Deceased/retired recipients: Where a ToV was made prior to death or retirement, it is disclosed in the relevant data year.

Healthcare Organisation (HCO): Any healthcare, medical or scientific organisation such as a hospital, clinic, foundation, university, other teaching institution or learned society (excluding patient organisations), through which one or more HCPs provide services and whose place of incorporation is in Norway.

1.2 Kind of ToVs

Organon discloses the following kinds of ToVs:

HCOs:

- Donations and Grants for supporting healthcare, scientific research or education (no benefit in return).

- Contributions to costs related to events (e.g., sponsorship agreements, booth/stand hire, satellite symposia).
- Fees for services and consultancy (and related expenses).

HCPs:

- Contributions to costs related to events (registration fees; travel and accommodation).
- Fees for service and consultancy (e.g., speaking, advisory services, medical writing, data analysis, development of educational materials, market research when the identity is known to Organon).

Research & Development (R&D):

ToVs related to non-clinical studies, clinical trials and prospective non-interventional studies that involve collection of patient data.

2. Disclosure's Scope**2.1 Products concerned**

This disclosure covers Transfers of Value related to prescription-only medicinal products. Transfers solely related to over-the-counter medicines or medical devices are not included.

2.2 Company concerned

This disclosure covers all relevant ToVs to recipients in Norway associated with the Organon group regardless of which Organon entity contracted with or paid a recipient.

2.3 Excluded ToVs

The following ToVs are excluded from disclosure:

- ToVs solely related to over-the-counter medicines.
- Ordinary course purchases and sales of medicines (e.g., between Organon and a pharmacy).
- Medical samples, investigational compounds and biological samples for study.
- Informational or educational materials and items of medical utility.
- ToVs to patient organisations (disclosed separately under relevant requirements).
- Meals and drinks.

2.4 ToVs date

Direct ToVs are disclosed based on the date Organon paid the ToV. E.g. if the payment occurred within the reporting period 1st January 2025 to 31st December 2025, the TOV would be disclosed in the 2025 report.

Indirect ToVs concerning travel and accommodation are disclosed based on the date the event took place. E.g. if the travelling occurred within the reporting period 1st January 2025 to 31st December 2025, the iTOV would be disclosed in the 2025 report.

2.5 Direct ToVs

Direct ToVs include, for example:

- Fees for service and consultancy paid, and related expenses, paid directly to HCPs or HCOs.
- Donations and Grants paid directly to HCOs.
- Sponsorships or contributions to costs of events paid to HCOs.

2.6 Indirect ToVs

Indirect ToVs include, for example:

- Travel and accommodation arranged or reimbursed through intermediaries for HCPs.
- Sponsorships or contributions to costs of events paid to third parties on behalf of HCOs.

2.7 Non-monetary ToVs

Not applicable.

2.8 ToVs in case of partial attendances or cancellation and refund

ToVs are reported on the basis of what Organon paid, not what the recipient ultimately received. Accordingly, in cases of partial attendance, the full amount paid by Organon is disclosed. Where an HCP cancels and no cost is incurred by Organon, no ToV is disclosed.

2.9 Cross-border activities

All ToVs to Norway recipients are disclosed in the Norway report, irrespective of which Organon entity contracted with, organised or paid for the activity.

2.10 R&D

R&D ToVs include those related to non-clinical studies (as per OECD Principles on Good Laboratory Practice), clinical trials (as per Directive 2001/20/EC), and prospective non-interventional studies involving data collection from, or on behalf of, HCPs/HCOs.

2.11 Voluntary disclosure

Not applicable.

3. Specific considerations

3.1 Country unique identifier

Organon uses internal commercial identifiers to uniquely identify recipients within our systems.

3.2 Self-incorporated HCP

Publication of value transfers is done on the name of the formal recipient. Thus, a fee paid to a legal entity such as an entity owned by an HCP will be recorded on the

company's name (which constitutes an HCO) and not on the individual's name because it is the entity that is the recipient of the value transfer.

3.3 Multi-year agreements

For multi-year agreements, Organon discloses the value in the year in which the ToV is made (i.e., when the cost is incurred/paid), with amounts reported for each calendar year accordingly.

4. Data protection legal basis

4.1 Consent collection

Not applicable. Organon relies on Legitimate Interests for publication of individual HCP data (see 4.2).

4.2 Legitimate interests

Organon have chosen to process personal data for the purposes of Transfer of Value using the legal basis of legitimate interests under Article 6(1)(f) GDPR, and outline this in the agreement between Organon and the data subject. This is communicated within contracts and letters of agreement. Individuals may object to processing by contacting privacyteam@organon.com. Organon assesses objections via a documented balancing test and will cease processing unless compelling legitimate grounds are demonstrated.

5. Form of disclosure

5.1 Date of publication

Latest last working day of June each year.

5.2 Disclosure platform

Disclosure is made via the Organon Norway website.

5.3 Disclosure language

English

6. Disclosure financial data

6.1 Currency

NOK. Where costs are incurred in other currencies, values are converted using the exchange rate applicable on the date the cost is incurred/posting date within Organon's finance systems.

6.2 VAT included or excluded

Indirect ToVs (e.g., travel and accommodation arranged on behalf of, or reimbursed to, HCPs) include VAT. Direct payment ToVs exclude VAT (Organon recovers VAT where applicable).

6.3 Calculation rules

Disclosed ToVs reflect the actual cost paid by Organon. In-kind/non-monetary ToVs (if any) are measured at Organon's cost. Refunds and credit notes are netted in the period they post, aligned to the ToV recognition rules described in Section 2.4.

7. Additional Information

For all queries contact: privacyteam@organon.com.